Stayble Therapeutics: Publication of year-end report 2021

Report this content

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is available as an attached document to this press release and on the Company’s website (Stayble Therapeutics).

Highlights during the fourth quarter (October – December 2021)

  • Stayble presented interim data from the ongoing phase 2b study and announced that the patient recruitment is still affected by the Covid-19 and that study results can be presented in 2023.

Highlights after the end of the period

  • No significant events that have had an impact on Stayble Therapeutics' financial position occurred after the period.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail